Subjective Cognitive Decline: Complaint Without Measurable Deficit
Placeholder: defining SCD as self-perceived decline with normal objective testing.
- ~25%: Prevalence 60+ (placeholder population estimate)
- ~6–8%: Annual conversion (placeholder MCI conversion rate)
- Normal: Testing sensitivity (placeholder neuropsych result)
- Memory: Symptom domain (placeholder most common complaint)
Defining the SCD construct
Placeholder text describing SCD diagnostic framework and criteria.
Distinguishing Normal Age-Related Change From Early Neurodegeneration
Placeholder: contrasting benign forgetfulness patterns with early pathological signs.
- Common: Benign forgetfulness (placeholder normative pattern)
- Progressive: Red-flag pattern (placeholder concerning trajectory)
- Key input: Informant report (placeholder corroboration source)
- Absent: Functional impact (placeholder SCD hallmark)
Normal aging benchmarks
Placeholder text on differentiating normative cognitive aging curves from disease.
Risk Factors That Raise Conversion Likelihood
Placeholder: cataloguing genetic, family, and clinical risk modifiers.
- Elevated risk: APOE4 carriers (placeholder genetic modifier)
- 2× risk: Family history (placeholder relative risk estimate)
- Additive: Vascular factors (placeholder comorbidity effect)
- Confounder: Depression history (placeholder overlapping symptom)
Stratifying by risk burden
Placeholder text describing cumulative risk factor scoring approach.
When to Consider Biomarker Testing
Placeholder: CSF, amyloid PET, and blood biomarker decision points.
- Available: CSF Aβ42/tau (placeholder biomarker modality)
- High cost: Amyloid PET (placeholder access constraint)
- Emerging: Blood biomarkers (placeholder plasma p-tau assay)
- Guides use: Pretest probability (placeholder testing threshold)
Biomarker decision criteria
Placeholder text on selecting candidates for biomarker workup.
Choosing Between Monitoring and Immediate Workup
Placeholder: final triage decision balancing risk and patient preference.
- 12 months: Routine follow-up (placeholder interval for low risk)
- 6 months: Enhanced monitoring (placeholder interval for moderate risk)
- Immediate: Urgent workup (placeholder high-risk pathway)
- Essential: Shared decision (placeholder patient involvement)
Final triage pathway
Placeholder text summarizing the monitoring-versus-workup decision tree.